Boehringer Ingelheim to launch production in Russia

14 June 2016

German family-owned pharma major Boehringer Ingelheim is expanding into the Russian pharmaceutical market through the localization of production for its drugs for the treatment of cardiovascular diseases, according to the company.

The production will take place at the facilities of the local firm Petrovax Farm in the Moscow region and at the initial stage will be limited by Actilyse (alteplase) and Metalize drugs. This will be the first time that these drugs will be produced by Boehringer outside Germany, reports The Pharma Letter’s local correspondent.

According to Boehringer and the data of the Russian Ministry of Health, cardiovascular diseases are currently the main cause of mortality in Russia. In 2014 they accounted for 50% of the total number of deaths in Russia. In 2015 heart attacks resulted in the death of 63,000 Russians, while about 420,000 Russians suffered from an ischemic stroke.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK